Antibody drug conjugates (ADCs) are formed by attaching drug substances to antibodies using a
special linker moiety. The ideal ADC will specifically target antigen-expressing cells and release
the drug in active form inside the cell. ADCs combine the specificity of monoclonal antibodies with
high potency of cytotoxic drugs, leading to highly improved therapeutic window and less side effects.
However, the current challenges in ADC technology are related to creating highly homogeneous ADC products
with excellent safety profile to fully utilize the benefits of targeted therapy.
Glykos’ breakthrough ADC technology utilizes novel hydrophilic glycopeptide linkers and site-specific conjugation to glycans or cysteines. Glykos has developed proprietary hydrophilic linker-payloads with both auristatin payloads targeting tubulin (MMAU) and anthracyclin payloads targeting DNA (PNU-EDA). The benefits include homogeneous drug-to-antibody ratio (DAR), excellent utility with hydrophobic drugs, highly increased tolerability, and significantly improved payload efficacy particularly against drug-resistant cells and low-abundance target antigens. Our linkers can be used with practically any monoclonal antibody and with a large selection of potent payloads making our technology highly flexible as it can be integrated into our clients existing development programs.
Glykos’ own pipeline includes cytotoxic ADCs against solid and hematological tumors as well as novel immune-oncology payloads targeting various cancer indications.